Jennifer Machado Soares, Thaila Quatrini Corrêa, Claudia Patricia Barrera Patiño, Isabella Salgado Gonçalves, Gabriel Grube Dos Santos, Gabriela Gomes Guimarães, Rebeca Vieira de Lima, Thalita Hellen Nunes Lima, Bruna Carolina Corrêa, Taina Cruz de Souza Cappellini, Maria Vitória Silva Pereira, Anna Luiza França de Oliveira Resende, Vladislav V Yakovlev, Kate Cristina Blanco, Vanderlei Salvador Bagnato
{"title":"Synergistic Paradigms in Infection Control: A Review on Photodynamic Therapy as an Adjunctive Strategy to Antibiotics.","authors":"Jennifer Machado Soares, Thaila Quatrini Corrêa, Claudia Patricia Barrera Patiño, Isabella Salgado Gonçalves, Gabriel Grube Dos Santos, Gabriela Gomes Guimarães, Rebeca Vieira de Lima, Thalita Hellen Nunes Lima, Bruna Carolina Corrêa, Taina Cruz de Souza Cappellini, Maria Vitória Silva Pereira, Anna Luiza França de Oliveira Resende, Vladislav V Yakovlev, Kate Cristina Blanco, Vanderlei Salvador Bagnato","doi":"10.1021/acsinfecdis.5c00369","DOIUrl":null,"url":null,"abstract":"<p><p>The increasing threat of antimicrobial resistance necessitates developing novel strategies to enhance the efficacy of existing antibiotics. This review explores the potential of antimicrobial photodynamic therapy (aPDT) as an adjunctive approach to antibiotic therapy. A systematic literature search was conducted in major scientific databases, focusing on studies published in the past decade investigating the synergistic effects of aPDT with antibiotics. Selected articles were analyzed based on their experimental approaches, bacterial targets, photodynamic parameters, and reported treatment outcomes. aPDT induces bacterial cell damage by generating reactive oxygen species (ROS), enhancing antibiotic susceptibility, and reducing required dosages. Furthermore, the review highlights promising research on optimizing treatment parameters and antibiotic combination strategies to maximize therapeutic outcomes. Despite its potential, aPDT faces obstacles to treatment standardization, variability in bacterial responses, and clinical implementation hurdles. These challenges require standardized protocols, further in vivo studies, and regulatory advancements to integrate aPDT into mainstream antimicrobial therapy. Conclusion: The synergy between aPDT and antibiotics represents a promising frontier in infection control, offering a safer, more effective, and resistance-mitigating strategy for bacterial infections. Future research should focus on refining treatment parameters, assessing long-term clinical impacts, and facilitating the widespread adoption of aPDT as a complementary antimicrobial approach.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.5c00369","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The increasing threat of antimicrobial resistance necessitates developing novel strategies to enhance the efficacy of existing antibiotics. This review explores the potential of antimicrobial photodynamic therapy (aPDT) as an adjunctive approach to antibiotic therapy. A systematic literature search was conducted in major scientific databases, focusing on studies published in the past decade investigating the synergistic effects of aPDT with antibiotics. Selected articles were analyzed based on their experimental approaches, bacterial targets, photodynamic parameters, and reported treatment outcomes. aPDT induces bacterial cell damage by generating reactive oxygen species (ROS), enhancing antibiotic susceptibility, and reducing required dosages. Furthermore, the review highlights promising research on optimizing treatment parameters and antibiotic combination strategies to maximize therapeutic outcomes. Despite its potential, aPDT faces obstacles to treatment standardization, variability in bacterial responses, and clinical implementation hurdles. These challenges require standardized protocols, further in vivo studies, and regulatory advancements to integrate aPDT into mainstream antimicrobial therapy. Conclusion: The synergy between aPDT and antibiotics represents a promising frontier in infection control, offering a safer, more effective, and resistance-mitigating strategy for bacterial infections. Future research should focus on refining treatment parameters, assessing long-term clinical impacts, and facilitating the widespread adoption of aPDT as a complementary antimicrobial approach.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.